16.1 Maternal Physiology & Pharmacokinetics Across Trimesters

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters

Pregnancy elicits widespread anatomical and physiological adaptations designed to sustain the developing fetus and prepare the parturient for delivery. For the nurse anesthetist, these changes dramatically alter airway management, cardiopulmonary reserve, drug pharmacokinetics, and maternal-fetal safety thresholds.

---

1. Cardiovascular System Alterations

Cardiovascular remodeling begins during the first trimester, peaks late in the second to early third trimester, and undergoes dynamic fluctuations during labor and the immediate postpartum period.

+---------------------------------------------------------------------------------------------------------+
|                               MATERNAL CARDIOVASCULAR ADAPTATIONS AT TERM                              |
+----------------------------+-----------------------+----------------------------------------------------+
| Parameter                  | Percentage Change     | Physiologic Mechanism & Clinical Significance       |
+----------------------------+-----------------------+----------------------------------------------------+
| **Intravascular Volume**   | +35% to +45% overall  | • Plasma volume expands by ~50% (1000-1500 mL)     |
|                            |                       | • Erythrocyte mass expands by ~20% to 30% (300 mL) |
|                            |                       | • Result: **Physiologic Anemia of Pregnancy**      |
|                            |                       |   (Normal term Hgb: 11-12 g/dL; Hct: 33-35%)       |
+----------------------------+-----------------------+----------------------------------------------------+
| **Cardiac Output (CO)**    | +40% to +50% at term  | • Stroke Volume (SV) increases by ~30%             |
|                            |                       | • Heart Rate (HR) increases by ~15% to 25% (10-20 bpm)|
|                            |                       | • Left ventricular hypertrophy & chamber dilation  |
+----------------------------+-----------------------+----------------------------------------------------+
| **Systemic Vascular        | -20% to -30%          | • Low-resistance uteroplacental vascular shunt     |
|   Resistance (SVR)**       |                       | • Vasodilation via Prostacyclin (PGI2), Nitric     |
|                            |                       |   Oxide (NO), and circulating relaxin/estrogen     |
+----------------------------+-----------------------+----------------------------------------------------+
| **Pulmonary Vascular       | -30% to -40%          | • Significant reduction in pulmonary resistance    |
|   Resistance (PVR)**       |                       | • Accommodates massive increase in right heart CO  |
+----------------------------+-----------------------+----------------------------------------------------+
| **Blood Pressure (MAP)**   | ↓ Mid-trimester,      | • SBP and DBP nadir at 24-28 weeks (5-10 mmHg drop)|
|                            | Normalizes at Term    | • Normalizes toward pre-pregnancy baseline at term |
+----------------------------+-----------------------+----------------------------------------------------+
| **Central Venous / PAOP**  | Unchanged             | • Unchanged despite massive intravascular expansion|
|                            |                       |   due to profound vascular compliance/capacitance  |
+----------------------------+-----------------------+----------------------------------------------------+

Hemodynamic Fluctuations During Labor & Postpartum Autotransfusion

Cardiac output surges dynamically throughout labor and delivery above pre-labor baseline levels:

• First Stage (Latent/Active Labor): CO increases by $+15%$ to $+30%$ during contractions.
• Second Stage (Pushing / Expulsive): CO increases by $+45%$ to $+50%$ due to pain, sympathetic activation, and maternal expulsive efforts.
• Immediate Postpartum Period (The Hemodynamic Peak): CO surges by $+60%$ to $+80%$ (up to $10 - 12 \text{ L/min}$) within minutes of delivery. This occurs because of:
  1. Uterine Autotransfusion: The contracted, empty uterus expels approximately $300 - 500 \text{ mL}$ of blood into the maternal venous circulation.
  2. Relief of Caval Compression: Complete decompression of the inferior vena cava (IVC) immediately restores full venous return to the right heart.

[!CAUTION] The Postpartum Heart Failure Trap: Parturients with pre-existing stenotic valvular heart disease (especially Mitral Stenosis or Aortic Stenosis) or cardiomyopathy are at the absolute highest risk for acute pulmonary edema and cardiovascular collapse immediately following placental delivery, not during induction or labor!

                      [LABOR & POSTPARTUM CARDIAC OUTPUT TRAJECTORY]

      Cardiac Output (% Above Pre-Pregnancy Baseline)
      100% |                                               /\  [Immediate Postpartum Peak: +80%]
       80% |                                              /  \  (Autotransfusion + IVC Relief)
       60% |                                  /\ (Stage 2)    \
       40% |        =========================   (Pushing)      \========== (Normalizes in 2-4 wks)
       20% |       / (Term Baseline: +40-50%)
        0% |______/
          Non-Preg   1st Tri   2nd Tri   3rd Tri   Stage 1   Stage 2   Postpartum

Aortocaval Compression Syndrome (Supine Hypotensive Syndrome)

From the 20th week of gestation onward, the gravid uterus compresses both the inferior vena cava and the descending abdominal aorta when the parturient is in the supine position.

• Vena Caval Compression: Obstructs venous return from the lower extremities, drastically reducing right ventricular end-diastolic volume, stroke volume, and cardiac output by up to $20 - 30%$. Symptoms include lightheadedness, diaphoresis, nausea, tachycardia, and profound hypotension.
• Aortic Compression: Compresses the aorta above the bifurcation, decreasing arterial perfusion pressure to the lower extremities and, critically, to the uterine arteries.
• Clinical Mandate: Always establish $15^\circ$ Left Uterine Displacement (LUD) or place a firm wedge under the right hip in every parturient $\ge 20$ weeks gestation during transport, regional anesthesia placement, surgery, and cardiopulmonary resuscitation.

                       [AORTOCAVAL COMPRESSION MECHANICS]

                 SUPINE (PATHOLOGIC)                 LEFT UTERINE DISPLACEMENT (LUD)
                 ===================                 ===============================
                   [Gravid Uterus]                          [Gravid Uterus]
                     |         |                                  /        
                     v         v                                 / (Tilted 15° Left)
                 [IVC]      [AORTA]                            v
                (Flattened/ (Compressed/                    [IVC]      [AORTA]
                 Occluded)   Hypoperfused)                 (Patent)    (Patent)
                     |         |
                     v         v
                 ↓ Preload   ↓ Uteroplacental Flow
                 ↓ CO & BP   → Fetal Bradycardia

Uteroplacental Perfusion Dynamics

Uterine blood flow (UBF) increases ten-fold from $50 - 100 \text{ mL/min}$ in the non-pregnant state to $700 - 900 \text{ mL/min}$ at term, accounting for $10 - 12%$ of total cardiac output. Crucially, the uteroplacental vascular bed is maximally dilated with ZERO autoregulation.

$\text{Uterine Blood Flow (UBF)} = \frac{\text{Uterine Arterial Pressure (UAP)} - \text{Uterine Venous Pressure (UVP)}}{\text{Uterine Vascular Resistance (UVR)}}$

Clinical determinants affecting UBF:

1. Decreased Perfusion Pressure (UAP - UVP): Caused by maternal systemic hypotension (sympathectomy from spinal/epidural, hemorrhage, aortocaval compression) or elevated uterine venous pressure (vena caval compression, Valsalva pushing, hypertonic uterine contractions).
2. Increased Vascular Resistance (UVR): Caused by endogenous catecholamines (maternal anxiety, severe labor pain), exogenous alpha-1 agonists in high doses, local anesthetic systemic toxicity (LAST), or preeclampsia/vasospasm.

[!NOTE] Phenylephrine vs. Ephedrine in Obstetrics: Historical teaching favored ephedrine due to concerns that phenylephrine-induced alpha-1 vasoconstriction would compromise UBF. However, modern evidence demonstrates that Phenylephrine is the first-line vasopressor of choice for post-spinal hypotension in obstetrics. Phenylephrine maintains maternal blood pressure while producing superior fetal acid-base profiles (higher umbilical artery pH and lower base deficit). Ephedrine crosses the placenta readily, stimulates fetal metabolism via beta-adrenergic receptors, and induces fetal lactic acidosis.

---

2. Respiratory System Alterations

Pregnancy-induced hormonal and mechanical changes dramatically alter maternal pulmonary mechanics, lung volumes, and arterial blood gas values.

+---------------------------------------------------------------------------------------------------------+
|                                 MATERNAL RESPIRATORY ALTERATIONS AT TERM                                |
+----------------------------+-----------------------+----------------------------------------------------+
| Parameter                  | Percentage Change     | Clinical Significance & Mechanistic Detail          |
+----------------------------+-----------------------+----------------------------------------------------+
| **Minute Ventilation (VE)**| +50% at term          | • Tidal Volume (VT) increases +40% to 45%          |
|                            |                       | • Respiratory Rate (RR) increases +10% to 15%      |
|                            |                       | • Driven by progesterone stimulating medullary ctr |
+----------------------------+-----------------------+----------------------------------------------------+
| **Functional Residual      | -20% to -30%          | • Diaphragm displaced cephalad by ~4 cm            |
|   Capacity (FRC)**         | (up to -40% supine)   | • Expiratory Reserve Volume (ERV) drops -20% to -25%|
|                            |                       | • Residual Volume (RV) drops -15% to -20%          |
+----------------------------+-----------------------+----------------------------------------------------+
| **Vital Capacity (VC)**    | Unchanged             | • Compensatory widening of subcostal angle         |
| **Total Lung Cap. (TLC)**  | Unchanged (-0% to -5%)|   (from 68° to 103°) preserves thoracic compliance |
+----------------------------+-----------------------+----------------------------------------------------+
| **Oxygen Consumption (VO2)**| +20% to +40% at term  | • Increased metabolic demand of fetus, placenta,   |
|                            | (+100% in labor)      |   and maternal cardiac/renal/respiratory work      |
+----------------------------+-----------------------+----------------------------------------------------+
| **Airway Resistance (Raw)**| -35% to -50%          | • Progesterone-mediated bronchial smooth muscle    |
|                            |                       |   relaxation decreases total airway resistance     |
+----------------------------+-----------------------+----------------------------------------------------+

Maternal Blood Gas Equilibrium: Compensated Respiratory Alkalosis

Progesterone acts directly as a respiratory stimulant on the central medullary chemoreceptors, shifting the carbon dioxide response curve to the left and increasing its slope. As a result, the pregnant patient chronically hyperventilates.

+---------------------------------------------------------------------------------------+
|                      ARTERIAL BLOOD GAS VALUES: PREGNANT VS. NON-PREGNANT             |
+--------------------+----------------------------+-------------------------------------+
| Blood Gas Variable | Non-Pregnant Baseline      | Term Pregnant Baseline              |
+--------------------+----------------------------+-------------------------------------+
| **pH**             | 7.35 – 7.45 (Mean: 7.40)   | **7.40 – 7.44** (Mildly alkalotic)  |
| **PaCO₂**          | 35 – 45 mmHg (Mean: 40)    | **28 – 32 mmHg** (Chronic hypocapnia)|
| **PaO₂**           | 80 – 100 mmHg              | **100 – 106 mmHg** (1st Tri); 95-100 (3rd Tri)|
| **Serum HCO₃⁻**    | 22 – 26 mEq/L (Mean: 24)   | **18 – 22 mEq/L** (Renal excretion) |
| **Base Excess**    | -2 to +2 mEq/L             | **-3 to -2 mEq/L**                  |
| **P50 (Hb-O2)**    | 26.7 mmHg                  | **30 mmHg** (Right-shifted curve)   |
+--------------------+----------------------------+-------------------------------------+

Physiologic Significance of Maternal P50 Right-Shift: Maternal hemoglobin P50 increases from $26.7 \text{ mmHg}$ to $30 \text{ mmHg}$ due to increased 2,3-DPG. This rightward shift facilitates oxygen unloading across the placenta. Conversely, Fetal Hemoglobin (HbF) has a P50 of $19 \text{ mmHg}$ (left-shifted curve due to poor binding to 2,3-DPG), creating a steep partial pressure gradient that pulls oxygen from maternal blood into fetal circulation (The Double Bohr Effect).

Mechanism of Rapid Maternal Arterial Desaturation

During induction of general anesthesia and apnea, parturients desaturate at an alarming rate compared to non-pregnant adults. The safe apnea time (time until $SpO_2 < 90%$) decreases from $\approx 8 \text{ minutes}$ in healthy non-pregnant adults to $< 2 - 3 \text{ minutes}$ in term parturients.

$\text{Desaturation Rate} \propto \frac{\text{Oxygen Consumption } (\dot{V}O_2)}{\text{Functional Residual Capacity } (FRC)}$

1. Diminished Oxygen Reservoir (FRC): FRC decreases by $20 - 30%$ upright and up to $40%$ supine. FRC falls below Closing Capacity (CC) in up to $50%$ of parturients when supine, causing small airway closure and shunt ($V/Q < 1$) during normal tidal breathing.
2. Accelerated Oxygen Consumption ($VO_2$): Metabolic oxygen demand increases by $20 - 40%$ at rest and $>100%$ during active labor.
3. Clinical Action: Thorough preoxygenation is mandatory: 8 vital capacity breaths of $100% \text{ O}_2$ over 60 seconds (or 3-5 minutes of tidal breathing at $>10 \text{ L/min}$) with an airtight mask seal, supplemented by continuous high-flow nasal cannula oxygen (THRIVE) during airway instrumentation.

The Obstetric Airway: Capillary Engorgement & Difficult Intubation

Estrogen induces profound mucosal hyperemia, glandular hyperactivity, and tissue edema throughout the upper respiratory tract (nasopharynx, oropharynx, larynx, and false vocal cords).

• Difficult Intubation Incidence: Difficult or failed tracheal intubation is 8 to 10 times higher in obstetrics ($1:250 - 1:300$) than in the general surgical population ($1:2000$).
• Airway Management Directives:
  • Avoid nasal instrumentation (nasal airways, nasogastric tubes, nasal ETTs) due to extreme vascularity and risk of severe epistaxis.
  • Downsize the endotracheal tube: use a 6.0 to 6.5 mm ID cuffed ETT (standard 7.0-8.0 tubes may cause vocal cord trauma or fail to pass through the narrowed glottis).
  • Utilize a short-handled laryngoscope blade to prevent the handle from impinging against hypertrophied breast tissue during insertion.

---

3. Gastrointestinal, Hepatic, and Renal Adaptations

+---------------------------------------------------------------------------------------------------------+
|                               GASTROINTESTINAL & HEPATORENAL ALTERATIONS                                |
+---------------------+-------------------------------+---------------------------------------------------+
| Organ System        | Physiologic Alteration        | Clinical Implications for Anesthesia              |
+---------------------+-------------------------------+---------------------------------------------------+
| **Gastrointestinal**| • Progesterone relaxes Lower  | • **High aspiration risk:** All parturients       |
|                     |   Esophageal Sphincter (LES)  |   $\ge 14-16$ weeks are considered "full stomach" |
|                     | • Stomach displaced cephalad  | • Barrier pressure ($P_{LES} - P_{gastric}$) drops|
|                     | • Placental gastrin secretion | • Gastric pH is lower; volume is increased        |
|                     | • Delayed emptying in labor   | • Opioids/pain further halt gastric motility      |
+---------------------+-------------------------------+---------------------------------------------------+
| **Hepatic**         | • Serum albumin drops ~20-30% | • Increased free unbound fraction of basic/acidic |
|                     | • Plasma pseudocholinesterase |   drugs (bupivacaine, rocuronium, diazepam)       |
|                     |   activity drops by ~25-30%   | • Prolonged succinylcholine duration is rare      |
|                     | • Alkaline Phosphatase rises  |   because volume of distribution is also expanded |
|                     |   2-3x (placental isoenzyme)  | • AST, ALT, Bilirubin, LDH do NOT change normally |
+---------------------+-------------------------------+---------------------------------------------------+
| **Renal**           | • Renal Blood Flow rises +60% | • **Lower baseline Serum Creatinine (0.4-0.6 mg/dL|
|                     | • GFR increases by +50%       |   and BUN (8-10 mg/dL)**; Cr >0.8 is abnormal     |
|                     | • Glycosuria & proteinuria    | • Proteinuria up to 300 mg/24h is normal          |
|                     |   (mild, up to 300 mg/day)    | • Rapid renal clearance of hydrophilic drugs      |
+---------------------+-------------------------------+---------------------------------------------------+

---

4. Hematology & The Hypercoagulable State

Pregnancy is a state of compensated, physiological hypercoagulability designed to limit peripartum hemorrhage. Estrogen drives enhanced hepatic production of procoagulant clotting factors while decreasing natural anticoagulant pathways.

+---------------------------------------------------------------------------------------------------------+
|                                 MATERNAL COAGULATION PROFILE AT TERM                                    |
+--------------------------------------+------------------------------------------------------------------+
| Coagulation Factor Alteration        | Clinical Value & Physiologic Context                             |
+--------------------------------------+------------------------------------------------------------------+
| **Factor I (Fibrinogen) ↑↑**         | • Increases +50% to +100% (**Normal at Term: 400 - 650 mg/dL**)  |
|                                      | • Level < 200 mg/dL represents critical consumption / DIC        |
+--------------------------------------+------------------------------------------------------------------+
| **Factors VII, VIII, IX, X, XII ↑**  | • Significant elevation in intrinsic & extrinsic clotting factors|
| **von Willebrand Factor (vWF) ↑**    | • Increases 2- to 3-fold, reducing bleeding in mild vWD          |
+--------------------------------------+------------------------------------------------------------------+
| **Protein S Activity ↓↓**            | • Significant reduction in free active Protein S                 |
| **Activated Protein C Resistance ↑** | • Physiologic resistance to APC develops in late pregnancy       |
| **Antithrombin III (ATIII) ↓/↔**     | • Borderline decrease or normal; relative deficiency             |
+--------------------------------------+------------------------------------------------------------------+
| **Fibrinolysis ↓**                   | • Placental PAI-1 and PAI-2 suppress clot lysis until delivery   |
+--------------------------------------+------------------------------------------------------------------+
| **Thromboembolism Risk**             | • **5- to 6-fold higher risk** of deep vein thrombosis and PE    |
+--------------------------------------+------------------------------------------------------------------+

Gestational Thrombocytopenia: Platelet counts drop progressively during pregnancy in $\approx 8%$ of healthy women due to hemodilution and accelerated platelet consumption in the uteroplacental bed. A platelet count between $100,000 - 150,000 /\text{mm}^3$ without systemic symptoms or bleeding history is benign gestational thrombocytopenia and does not preclude neuraxial anesthesia.

---

5. Obstetric Pharmacokinetics & Placental Drug Transfer

Anesthetic Sensitivity & Reduced Dosing Requirements

1. Inhalational Anesthetics: Minimum Alveolar Concentration (MAC) is reduced by 30% to 40% across all volatile agents starting as early as 8-12 weeks gestation. This is mediated by increased progesterone levels and elevated central $\beta$-endorphin activity enhancing GABAergic transmission. Furthermore, the elevated $V_A / FRC$ ratio accelerates both inhalational induction and emergence.
2. Neuraxial Local Anesthetics: Spinal and epidural local anesthetic dose requirements are reduced by 25% to 40% due to:
   • Epidural Space Compression: IVC compression engorges the epidural venous plexus (Batson's plexus), reducing both the volume of the epidural space and the volume of lumbar CSF within the subarachnoid space.
   • Enhanced Neural Sensitivity: Progesterone alters neural axonal membrane lipid dynamics, making sodium channels more susceptible to local anesthetic blockade.
   • Spinal Curvature: Exaggerated lumbar lordosis promotes enhanced cephalad spread of hyperbaric intrathecal solutions.

Principles of Placental Drug Transfer

Placental transfer occurs primarily via passive simple diffusion, governed by Fick's Law:

$\text{Rate of Transfer} = \frac{K \cdot A \cdot (C_m - C_f)}{D}$

Where $K$ is diffusion constant, $A$ is surface area, $(C_m - C_f)$ is concentration gradient, and $D$ is membrane thickness.

+---------------------------------------------------------------------------------------------------------+
|                                 PLACENTAL DRUG CROSSING CHARACTERISTICS                                  |
+--------------------------------------+------------------------------------------------------------------+
| Physico-Chemical Factor Favoring Transfer | Physico-Chemical Factor Preventing Transfer                 |
+--------------------------------------+------------------------------------------------------------------+
| • **Low Molecular Weight (< 500 Da)** | • **High Molecular Weight (> 1000 Da)**                         |
| • **High Lipid Solubility (Lipophilic)**| • **High Water Solubility / High Ionization**                  |
| • **Low Maternal Protein Binding**   | • **High Maternal Protein Binding**                              |
| • **Non-Ionized Molecular Fraction** | • **Highly Quaternary Ammonium Structure**                       |
+--------------------------------------+------------------------------------------------------------------+

+---------------------------------------------------------------------------------------------------------+
|                                DRUG CLASSIFICATION BY PLACENTAL TRANSFER                                |
+------------------------------------+--------------------------------------------------------------------+
| DRUGS THAT CROSS THE PLACENTA      | DRUGS THAT DO NOT CROSS (or cross negligibly)                      |
| *(Low MW, Lipophilic, Non-ionized)*| *(Mnemonic: **"He Is Going Nowhere Soon"**)*                       |
+------------------------------------+--------------------------------------------------------------------+
| • **Volatile Anesthetics** (all)   | • **H**eparin / LMWH (High MW, polar polyanion)                    |
| • **Propofol, Etomidate, Ketamine**| • **I**nsulin (High MW protein, 5800 Da)                           |
| • **Opioids** (Fentanyl, Morphine) | • **G**lycopyrrolate (Quaternary amine, charged, polar)            |
| • **Benzodiazepines** (Midazolam)  | • **N**euromuscular Blockers: Succinylcholine, Rocuronium,        |
| • **Local Anesthetics** (Lido, Bupi)|   Vecuronium, Cisatracurium (Fully ionized quaternary ammoniums)   |
| • **Atropine & Scopolamine**       | • **S**ugammadex (Cyclodextrin macromolecule, 2178 Da)             |
| • **Beta-Blockers** (Labetalol)    |                                                                    |
| • **Ephedrine & Clonidine**        |                                                                    |
+------------------------------------+--------------------------------------------------------------------+

The Clinical Phenomenon of Fetal Ion Trapping

Local anesthetics (e.g., lidocaine, bupivacaine) and opioids are weak bases. In the maternal circulation ($pH \approx 7.40$), a significant portion of the drug exists in the un-ionized, lipid-soluble state ($B$), which readily diffuses across the placental syncytiotrophoblast.

If the fetus is distressed, asphyxiated, or acidemic ($pH \approx 7.10 - 7.20$), the lower fetal pH drives the equilibrium toward the ionized conjugate acid state ($BH^+$):

$B + H^+ \rightleftharpoons BH^+ \quad (\text{Ionized, lipid-insoluble form})$

Because ionized molecules cannot diffuse back across lipid cell membranes, the drug becomes trapped within the fetal circulation, leading to toxic accumulation, neonatal myocardial depression, and severe neurobehavioral depression.